Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
Hemasphere|August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma NetworkGrigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)Naveen S Vasudev, Gemma Ainsworth, Sarah Brown, et al.Thrombosis and Haemostasis|September 17, 2021
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT StudyIsabelle Mahé, Giancarlo Agnelli, Cihan Ay, et al.Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic AdenocarcinomaEric Van Cutsem, Margaret A Tempero, Darren Sigal, et al.Health Technology Assessment (Winchester, England)|September 9, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCTFiona Collinson, Kara-Louise Royle, Jayne Swain, et al.The New England Journal of Medicine|March 31, 2025
Extended Reduced-Dose Apixaban for Cancer-Associated Venous ThromboembolismIsabelle Mahé, Marc Carrier, Didier Mayeur, et al.BMJ Open|May 1, 2016
Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocolHolger J Schünemann, Matthew Ventresca, Mark Crowther, et al.The Lancet. Haematology|September 25, 2020
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysisHolger J Schünemann, Matthew Ventresca, Mark Crowther, et al.Pageof 12